Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human Siglec-15 / CD33L3 Protein, Fc,Avitag™,  25 µg  

Recombinant Biotinylated Human Siglec-15 / CD33L3 Protein, Fc,Avitag™, 25 µg

Recombinant Biotinylated Human Siglec-15 / CD33L3 Protein, AA Phe 20 - Thr 263, expressed from human 293 cells (HEK293), Fc-tag, Avitag™

Synonym: recombinant, human, protein, CD33 antigen-like 3, SIGLEC-15, CD33L3, sialic acid-binding Ig-like lectin 15, Siglec15, Siglec-15

More details

SG5-H82F5-25

Availability: within 7 days

455,00 €

Background
Siglec-15 is a DAP12-associated immunoreceptor, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Siglecs are cell surface proteins that bind sialic acid. They are found primarily on the surface of immune cells and are a subset of the I-type lectins. Siglec-15 consisting of immunoglobulin (Ig)-like domains, transmembrane domain and a short cytoplasmic tail. Siglec-15 is that recognizes sialylated glycans and regulates osteoclast differentiation. Siglec-15 is a potential therapeutic target for osteoporosis and plays a conserved regulatory role in the immune system of vertebrates.

Source
Recombinant Biotinylated Human Siglec-15 protein, Fc-tag, Avitag (SG5-H82F5) is expressed from human 293 cells (HEK293). It contains AA Phe 20 - Thr 263 (Accession # Q6ZMC9-1).
Predicted N-terminus: Phe 20

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 54.8 kDa. The protein migrates as 58 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer"
Shafi, Aung, Xirou et al
Lab Invest (2022) 102 (10), 1143-1149
(2)  "Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis"
Jiang, Qi, Liu et al
Front Oncol (2022) 12, 1073932
(3)  "Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy"
Zhou, Wang, Zhang et al
JAMA Netw Open (2023) 6 (1), e2250965
Showing 1-3 of 84 papers.